Latest Insider Transactions at Neogenomics Inc (NEO)
This section provides a real-time view of insider transactions for Neogenomics Inc (NEO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEOGENOMICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEOGENOMICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Alicia C Olivo General Counsel |
SELL
Open market or private sale
|
Direct |
1,049
-2.28%
|
$15,735
$15.74 P/Share
|
|
May 11
2024
|
Melody Harris Chf Ops Off, Pres, Informatics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,722
-1.57%
|
$24,108
$14.86 P/Share
|
|
May 11
2024
|
Melody Harris Chf Ops Off, Pres, Informatics |
BUY
Exercise of conversion of derivative security
|
Direct |
7,068
+6.04%
|
-
|
|
May 11
2024
|
Jeffrey Scott Sherman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,010
+8.31%
|
-
|
|
May 11
2024
|
Jeffrey Scott Sherman Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,167
-2.28%
|
$44,338
$14.86 P/Share
|
|
May 11
2024
|
Warren Stone Chief Commerical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,224
+9.02%
|
-
|
|
May 11
2024
|
Warren Stone Chief Commerical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-2.51%
|
$32,774
$14.86 P/Share
|
|
May 11
2024
|
Alicia C Olivo General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,004
+13.05%
|
-
|
|
May 11
2024
|
Alicia C Olivo General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,584
-3.86%
|
$22,176
$14.86 P/Share
|
|
May 11
2024
|
Christopher M Smith Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
96,126
+6.74%
|
-
|
|
May 11
2024
|
Christopher M Smith Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,913
-2.91%
|
$264,782
$14.86 P/Share
|
|
May 01
2024
|
Alicia C Olivo General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
652
-1.86%
|
-
|
|
May 01
2024
|
Greg D Aunan Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
937
-6.09%
|
-
|
|
Mar 04
2024
|
Lynn A. Tetrault Director |
SELL
Open market or private sale
|
Direct |
6,112
-10.88%
|
$91,680
$15.97 P/Share
|
|
Feb 15
2024
|
Alicia C Olivo General Counsel |
SELL
Open market or private sale
|
Direct |
2,587
-6.91%
|
$36,218
$14.96 P/Share
|
|
Jan 01
2024
|
Melody Harris Chf Ops Off, Pres, Informatics |
SELL
Payment of exercise price or tax liability
|
Direct |
7,123
-6.47%
|
-
|
|
Dec 07
2023
|
Jeffrey Scott Sherman Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,147
-6.09%
|
-
|
|
Dec 01
2023
|
Warren Stone Chief Commerical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,431
-6.09%
|
-
|
|
Nov 17
2023
|
Alicia C Olivo General Counsel |
SELL
Open market or private sale
|
Direct |
2,669
-6.7%
|
$48,042
$18.39 P/Share
|
|
Sep 30
2023
|
Alicia C Olivo General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
14
-0.04%
|
-
|
|
Sep 01
2023
|
Alicia C Olivo General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,666
-4.06%
|
-
|
|
Aug 01
2023
|
Alicia C Olivo General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
14
-0.03%
|
-
|
|
Jun 01
2023
|
Vishal Sikri President Advanced Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
21,406
-14.35%
|
-
|
|
May 22
2023
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,507
+2.61%
|
$16,577
$11.6 P/Share
|
|
May 01
2023
|
Alicia C Olivo General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
662
-1.6%
|
-
|
|
Apr 01
2023
|
Shashikant Kulkarni Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,759
-4.35%
|
-
|
|
Mar 02
2023
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-0.39%
|
-
|
|
Mar 01
2023
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
880
-2.86%
|
-
|
|
Jan 01
2023
|
Melody Harris Chf Ops Off, Pres, Informatics |
BUY
Grant, award, or other acquisition
|
Direct |
108,225
+50.0%
|
-
|
|
Dec 31
2022
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
959
-3.02%
|
-
|
|
Dec 05
2022
|
Jeffrey Scott Sherman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133,809
+45.0%
|
-
|
|
Dec 01
2022
|
Warren Stone Chief Commerical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
89,206
+50.0%
|
-
|
|
Nov 03
2022
|
David Brian Perez Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,300
+50.0%
|
-
|
|
Nov 01
2022
|
Cynthia J Dieter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,141
+29.29%
|
-
|
|
Aug 15
2022
|
Christopher M Smith Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
602,219
+40.3%
|
-
|
|
Aug 01
2022
|
David Sholehvar President, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
12,352
+22.23%
|
-
|
|
Aug 01
2022
|
Shashikant Kulkarni Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,704
+27.28%
|
-
|
|
Jun 22
2022
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
57
-0.31%
|
-
|
|
Jun 10
2022
|
Lynn A. Tetrault Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+22.15%
|
-
|
|
Jun 10
2022
|
David Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+47.52%
|
-
|
|
Jun 10
2022
|
Rachel A Stahler Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+42.17%
|
-
|
|
Jun 10
2022
|
Alison L. Hannah Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+12.65%
|
-
|
|
Jun 10
2022
|
Bruce K Crowther Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+19.28%
|
-
|
|
Jun 10
2022
|
Stephen M Kanovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+38.59%
|
-
|
|
Jun 10
2022
|
Michael Aaron Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,556
+43.24%
|
-
|
|
Jun 01
2022
|
Vishal Sikri President Advanced Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
148,455
+50.0%
|
-
|
|
May 18
2022
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+7.85%
|
$23,338
$7.27 P/Share
|
|
Apr 28
2022
|
William Bonello Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,727
+2.9%
|
$40,089
$7.52 P/Share
|
|
Apr 01
2022
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,305
+34.15%
|
-
|
|
Apr 01
2022
|
David Sholehvar President, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
30,864
+50.0%
|
-
|